MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Guidelines for STEMI
Key messages from the ACC/AHA/SCAI 2009 focused update for the management of ST-elevation myocardial infarction.
By Jeffery M. Sparling, MD; Pinak B. Shah, MD; and David O. Williams, MD
CHIEF MEDICAL EDITOR'S PAGE: Primary PCI for STEMI
Managing Paravalvular Leaks After TAVR
Will next-generation percutaneous valve technologies address this current limitation?
By Satpal S. Arri, BSc, MRCP, and David Hildick-Smith, MD, FRCP
Transapical TAVR Devices
An era of rapid evolution in transcatheter aortic valve replacement technology.
By Michael A. Borger, MD, PhD; Joerg Seeburger, MD, PhD; Johannes Blumenstein, MD; David M. Holzhey, MD, PhD; and Friedrich W. Mohr, MD, PhD
Percutaneous Mitral Valve Repair Devices Beyond MitraClip
A review of devices in development for the percutaneous treatment of mitral regurgitation.
By Jonathan Marvin Tobis, MD, and Islam Abudayyeh, MD, MPH
THV Expansion
By Ted E. Feldman, MD, MSCAI, FACC, FESC
An Interview With Dee Dee Wang, MD, FACC, FASE, FSCCT, FSCAI
Dr. Wang shares insights on building an interventional imaging program and recent steps forward in the field, the future of three- and four-dimensional virtual and physical printing, and the impact of the American College of Cardiology’s Emerging Faculty program on the field of interventional imaging.
JETSTENT Demonstrates Benefit of Rheolytic Thrombectomy
March 16, 2010—The American College of Cardiology (ACC) announced that findings from the JETSTENT study demonstrated that conducting rheolytic thrombectomy before direct infarct-related artery stenting in patients with acute ST-segment elevation myocardial infarctions (STEMI) produced better clinical results than performing direct stenting alone.
JETSTENT Study Demonstrates Benefit of Rheolytic Thrombectomy Before Stenting in STEMI Patients
Interventional Therapies for Heart Failure
BiVacor Receives Grant to Support Clinical Trials for Total Artificial Heart
February 20, 2024—BiVacor, a clinical-stage medical device company based in Australia and California, announced an award of US$13 million from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP).